Navigation Links
NexBio Completes First-in-Man Clinical Trial With DAS181 (Fludase(R)) and Strengthens Clinical Leadership
Date:1/19/2009

SAN DIEGO, Jan. 19 /PRNewswire/ -- NexBio announces the completion of its First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug candidate for influenza. The single-dose, escalating Phase I study completed in December 2008 was designed to assess DAS181 safety in healthy subjects. The study drug was well tolerated at all dose levels. DAS181 is a novel broad-spectrum drug candidate for prophylaxis and treatment of respiratory infections by all variations of influenza virus, including the types of the virus that may cause a potential influenza pandemic. In addition, DAS181 also has the potential for prophylaxis and treatment of influenza-like illness due to other respiratory viruses, including the parainfluenza virus which may cause serious respiratory illness similar to influenza for which there is no approved vaccine or therapeutic. The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

DAS181, a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and parainfluenza viruses from infecting the human body or from amplifying in infected individuals. DAS181 effectively inhibits numerous strains of influenza and parainfluenza virus in cell culture and in animal models. Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with the currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance.

To strengthen DAS181 clinical development, NexBio announces the hiring of Ronald B. Moss, M.D., as NexBio's Executive Vice President of Clinical Development & Medical Affairs. Dr. Moss brings 22 years of research and clinical experience, including 15 y
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NexBio to Present at 2007 BIOCOM Investor Conference
2. Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered
3. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
4. InSet Technologies Completes $25 Million Financing
5. AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
6. Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC
7. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
8. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
9. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
10. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
11. Hard To Treat Diseases (HTDS) Completes E Europe Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Healthpointe is proud to announce that ... and ankle reconstruction surgeries to assist patients with severe ... specializes in the diagnosis and treatment of sports medicine, ... also trained to perform advanced Foot and Ankle Reconstruction ... is also fluent in Spanish. , Reconstructive surgical procedures ...
(Date:9/30/2014)... TX (PRWEB) September 30, 2014 ... Industry, 2009-2019 is a professional and in-depth market ... report firstly reviews the basic information of Cialis ... report then explores global and China’s top manufacturers ... value, and market share etc. , The report ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 To mark ... Editorial Board of Living with a Disability magazine ... light on hematological disorders as disabling conditions. ... more than a diagnosis to establish a disability related ... thrombocytomenia, myelofibrosis, hereditary telangiectasia, coagulation defects, polycythemia vera, and ...
(Date:9/30/2014)... Catalent Pharma Solutions (Stand 2C9), ... and development solutions for drugs, biologics and consumer ... the 25th Annual CPhI Worldwide Exhibition to be ... 9th. , Catalent is showcasing a number of ... show, including its facilities in China and Japan, ...
(Date:9/30/2014)... Jiwa Law Corporation, a personal injury law firm in Vancouver, ... free consultation for personal injury claims of their clients. This ... first time to meet the Vancouver ICBC lawyers will not ... what their rights are. The experts at Jiwa Law Corporation ... them what the law firm can do regarding their claim. ...
Breaking Medicine News(10 mins):Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 2Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 3Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2
... Journal of the American Heart Association, had said that ... risk of heart attacks and developing heart disease than ... blood pressure remaining between 120 and 139, and the ... Blood pressure hovering in any one of these two ...
... the link between alcohol and certain type of cancers, ... DNA repair pathways. ,The study examined the reaction ... induce cancer formation, found in alcohol) with polyamines - ... usually considered to be beneficial to the body because ...
... Latest research shows that drinking coffee could decrease the ... two cohort studies that showed self-reported frequency of coffee ... adjustment for potential confounders, researchers say they found that ... almost 30 per cent, while those drinking one or ...
... A new innovative vaccine for flu is under pre-clinical phase ... protection against flu. //, ,Flu is caused by virus ... virus. . Flu is an extremely contagious condition and makes ... serious consequences: According to the World Health Organization, on average ...
... are working on using virtual reality to help patients ... ,In this research, scientists are creating simulating virtual realities ... through the similar experiences they had felt when they ... had left them unable to cope reality. Called exposure ...
... Wales may be one of the first scientists to develop ... is no single test that could exactly identify the disease.//, ... latest issue of the journal Psychiatry Research said that this ... effective as their tool can safely distinguish between the two ...
Cached Medicine News:Health News:Risk Of Heart Attack Increase From Pre-Hypertension 2Health News:New Flu Vaccine Can Give Lifetime Protection 2Health News:Schizophrenia Gets A New Diagnostic Tool 2
(Date:9/30/2014)... ANGELES , Sept. 30, 2014   Easy ... shopping destination , today announced that it now offers ... . AirSense CPAPs are the first sleep apnea therapy ... it simple and easy to track and share real-time ... overall effectiveness of their CPAP therapy.  In addition, the ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... , Sept. 30, 2014 The Chinese wound ... population and rise in the incidence of lifestyle diseases, ... and in affordability of better quality of wound care ... market. Universal coverage of public health insurance schemes and ... stimulate demand. Based on the findings of primary and ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2China Wound Care Market 2China Wound Care Market 3
Polyester ribbon impregnated with conjugated Protein G - .13 OD per sq. cm....
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... glass (1.5x) Gonio lens will enable visualization ... 4 mirror lens is the industry preferred ... and features : , Crispest, clearest ... previously unattainable with Gonio lenses., 4 equally ...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: